Barclays analyst Andrew Mok raised the firm’s price target on Alignment Healthcare to $7 from $4.50 and keeps an Underweight rating on the shares. The company reported a solid quarter with membership growth ahead of estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare sees FY24 revenue $2.61B-$2.64B, consensus $2.52B
- Alignment Healthcare sees Q3 revenue $655M-$665M, consensus $630.25M
- Alignment Healthcare reports Q2 EPS (13c), consensus (14c)
- Better Health Outcomes for Seniors, Improved Access to Care and Reduced Environmental Footprint Are Top Achievements Noted in Alignment Healthcare’s 3rd Annual ESG Report
- Alignment Healthcare price target raised to $12 from $9 at Stifel